Therapeutic approaches for prion disorders.
Prion diseases are lethal for both humans and animals, and affected individuals die after several months following a rapid disease progression. Although researchers have attempted for decades to develop effective therapeutics for the therapy of human prion disorders, until now no efficient drug has been available on the market for transmissible spongiform encephalopathy (TSE) treatment or cure. Approximately 200 patients worldwide have died or suffer from variant Creutzfeldt-Jakob disease (CJD). Incidences for sporadic and familial CJD are approximately 1.5-2 per million per year and one per 10 million per year, respectively, in Europe. This review summarizes classical and modern trials for the development of effective anti-TSE drugs, introduces potential effective delivery systems, such as lentiviral and adeno-associated virus systems for antiprion components, including antibodies and siRNAs, and presents vaccination trials. Most of the antiprion drugs target prion protein PrP(c) and/or PrP(Sc). Alternative targets are receptors and coreceptors for PrP, that is, the 37/67-kDa laminin receptor and heparan sulfate proteoglycanes. We review clinical trials for the treatment of TSEs and describe hindrances and chances for a breakthrough in therapy of prion disorders.
Laboratorium für Molekulare Biologie, Genzentrum, Institut für Biochemie der LMU München, München, Germany. ludewigs@lmb.uni-muenchen.de
Heike
H
Ludewigs
Chantal
C
Zuber
Karen
K
Vana
Daphne
D
Nikles
Inga
I
Zerr
Stefan
S
Weiss
D000818:Animals; D002986:Clinical Trials as Topic; D003937:Diagnosis, Differential; D018450:Disease Progression; D016503:Drug Delivery Systems; D006801:Humans; D017096:Prion Diseases / Q000175:diagnosis / Q000188:drug therapy*; D034622:RNA Interference; D014611:Vaccination